{"schema_version":"secwatch.filing_event.v1","accession":"0000078003-25-000167","form_type":"8-K","ticker":"PFE","cik":"0000078003","company_name":"PFIZER INC","filed_at":"2025-12-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.145531+00:00","generated_at":"2026-05-16T13:07:50.175008+00:00","sec_items":["7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Pfizer revises FY2025 revenue to ~$62B (from $61-64B), provides FY2026 EPS guidance $2.80-3.00","bullets":["Revised FY2025 revenue guidance to ~$62.0B from prior $61-64B; reaffirmed adjusted diluted EPS $3.00-3.15.","FY2026 revenue guidance $59.5-62.5B; adjusted diluted EPS $2.80-3.00; tax rate ~15% vs ~11%.","COVID-19 product revenues ~$5.0B in 2026 (vs ~$6.5B in 2025); LOE impact ~$1.5B.","Adjusted SI&A $12.5-13.5B, R&D $10.5-11.5B in 2026; investing in PD-1 x VEGF bispecific and Metsera programs."],"urls":{"canonical":"https://secwatch.observer/filing/0000078003-25-000167","json":"https://secwatch.observer/filing/0000078003-25-000167.json","markdown":"https://secwatch.observer/filing/0000078003-25-000167.md","text":"https://secwatch.observer/filing/0000078003-25-000167.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/78003/000007800325000167/0000078003-25-000167-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/78003/000007800325000167/pfe-20251216.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:07:50.175008+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}